menu
    • menu
    [{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"},{"orgOrder":0,"company":"University of Karachi","sponsor":"The Searle Company LTD., Pakistan.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"University of Karachi \/ The Searle Company LTD., Pakistan.","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ The Searle Company LTD., Pakistan."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Neuraxpharm"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OWP Pharmaceuticals \/ Eversana","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Eversana"},{"orgOrder":0,"company":"Grete Andersen, MD","sponsor":"GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Grete Andersen, MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Grete Andersen, MD \/ GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab","highestDevelopmentStatusID":"1","companyTruncated":"Grete Andersen, MD \/ GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab"}]

    Find Clinical Drug Pipeline Developments & Deals for Lamotrigine

    Menu

    Lamotrigine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Gains FDA Approval For Lamotrigine Extended-Release Tablets USP

                            Details : Lamictal XR-Generic (lamotrigine) is a sodium channel alpha subunit blocker, which is indicated for adjunctive therapy for primary generalized tonic-clonic seizures & partial-onset seizures.

                            Product Name : Lamictal XR-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2024

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Gains USFDA Approval For Lamotrigine Extended-Release Tablets

                            Details : Lamotrigine is a voltage-sensitive sodium channel inhibitor, indicated for adjunctive therapy for primary generalised tonic-clonic seizures and partial-onset seizures in 13 years and above patients.

                            Product Name : Lamictal XR-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2024

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Desitin Arzneimittel

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditio...

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 10, 2024

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Grete Andersen, MD

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Grete Andersen, MD

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Myotonia - Lamotrigine Versus Namuscla

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Myotonia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2022

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OWP Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            OWP Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuro...

                            Details : Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety diso...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2021

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Karachi

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            University of Karachi

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : The Searle Company LTD., Pakistan.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tab...

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2021

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : The Searle Company LTD., Pakistan.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Cau...

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Glenmark Pharmaceuticals

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark’s CNS Product Portfolio

                            Details : Aquistion covers the lead products include the branded generics Cital® and Lamotrix® (lamotrigine), both relevant brands in their respective markets. With branded generics commanding the dominant share of market, Poland has the highest penetration of g...

                            Product Name : Lamotrix

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth